NO20041339L - Spiro-hydantoin-forbindelser anvendelige som anti-inflammatoriske midler - Google Patents

Spiro-hydantoin-forbindelser anvendelige som anti-inflammatoriske midler

Info

Publication number
NO20041339L
NO20041339L NO20041339A NO20041339A NO20041339L NO 20041339 L NO20041339 L NO 20041339L NO 20041339 A NO20041339 A NO 20041339A NO 20041339 A NO20041339 A NO 20041339A NO 20041339 L NO20041339 L NO 20041339L
Authority
NO
Norway
Prior art keywords
inflammatory agents
compounds useful
spirohydantoin compounds
spirohydantoin
useful
Prior art date
Application number
NO20041339A
Other languages
English (en)
Norwegian (no)
Other versions
NO20041339D0 (no
Inventor
Eric Antoine Nicolai
Murali T G Dhar
Dominique Potin
Magaili Jeannine Bland Maillet
Michele Launay
Edwin J Iwanowicz
Original Assignee
Cerep Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cerep Sa filed Critical Cerep Sa
Publication of NO20041339D0 publication Critical patent/NO20041339D0/no
Publication of NO20041339L publication Critical patent/NO20041339L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/96—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
NO20041339A 2001-10-01 2004-03-31 Spiro-hydantoin-forbindelser anvendelige som anti-inflammatoriske midler NO20041339L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US32636101P 2001-10-01 2001-10-01
US35411302P 2002-02-04 2002-02-04
US40025902P 2002-08-01 2002-08-01
PCT/US2002/031283 WO2003029245A1 (en) 2001-10-01 2002-09-30 Spiro-hydantoin compounds useful as anti-inflammatory agents

Publications (2)

Publication Number Publication Date
NO20041339D0 NO20041339D0 (no) 2004-03-31
NO20041339L true NO20041339L (no) 2004-05-24

Family

ID=27406458

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20041339A NO20041339L (no) 2001-10-01 2004-03-31 Spiro-hydantoin-forbindelser anvendelige som anti-inflammatoriske midler

Country Status (23)

Country Link
US (4) US6977267B2 (sr)
EP (1) EP1432700B1 (sr)
JP (1) JP4394442B2 (sr)
KR (1) KR20040041649A (sr)
CN (1) CN1596253A (sr)
AR (1) AR036663A1 (sr)
AT (1) ATE447565T1 (sr)
BR (1) BR0213025A (sr)
CA (1) CA2462112A1 (sr)
DE (1) DE60234264D1 (sr)
ES (1) ES2339107T3 (sr)
GE (1) GEP20063767B (sr)
HR (1) HRP20040311A2 (sr)
HU (1) HUP0402338A3 (sr)
IL (1) IL160990A0 (sr)
IS (1) IS7197A (sr)
MX (1) MXPA04002993A (sr)
NO (1) NO20041339L (sr)
NZ (1) NZ531870A (sr)
PE (1) PE20030845A1 (sr)
PL (1) PL369337A1 (sr)
RS (1) RS26604A (sr)
WO (1) WO2003029245A1 (sr)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2518465A1 (en) * 2003-03-25 2004-10-14 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US7700583B2 (en) 2003-04-11 2010-04-20 High Point Pharmaceuticals, Llc 11β-hydroxysteroid dehydrogenase type 1 active compounds
ATE482747T1 (de) * 2003-04-11 2010-10-15 High Point Pharmaceuticals Llc Neue amide derivate und deren pharmazeutische verwendungen
US7638638B2 (en) 2003-05-14 2009-12-29 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US7678909B1 (en) 2003-08-13 2010-03-16 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
KR20060041309A (ko) * 2003-08-13 2006-05-11 다케다 야쿠힌 고교 가부시키가이샤 ４-피리미돈 유도체 및 펩티딜 펩티다제 저해제로서의 그의용도
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
JP2007505121A (ja) * 2003-09-08 2007-03-08 武田薬品工業株式会社 ジペプチジルぺプチダーゼ阻害剤
WO2005030751A2 (en) * 2003-09-08 2005-04-07 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7199125B2 (en) 2003-10-02 2007-04-03 Bristol-Myers Squibb Company Spiro-cyclic compounds useful as anti-inflammatory agents
JP5105578B2 (ja) 2003-11-05 2012-12-26 サーコード バイオサイエンス インコーポレイテッド 細胞接着のモジュレーター
EP1709193B1 (en) 2003-12-19 2011-03-16 The Regents of The University of California Methods and materials for assessing prostate cancer therapies
WO2005099693A2 (en) 2004-02-24 2005-10-27 The Regents Of The University Of California Methods and materials for assessing prostate cancer therapies and compounds
US7732446B1 (en) 2004-03-11 2010-06-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
EA013427B1 (ru) * 2004-03-15 2010-04-30 Такеда Фармасьютикал Компани Лимитед Ингибиторы дипептидилпептидазы
JP2008501714A (ja) * 2004-06-04 2008-01-24 武田薬品工業株式会社 ジペプチジルペプチダーゼインヒビター
EP2433943B1 (en) 2004-07-01 2013-09-11 Daiichi Sankyo Company, Limited Intermediates for thienopyrazole derivatives having PDE7 inhibitory activity
WO2006019965A2 (en) 2004-07-16 2006-02-23 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US7375237B2 (en) 2004-08-18 2008-05-20 Bristol-Myers Squibb Company Pyrrolizine compounds useful as anti-inflammatory agents
TW200616634A (en) * 2004-10-01 2006-06-01 Bristol Myers Squibb Co Crystalline forms and process for preparing spiro-hydantoin compounds
US8110581B2 (en) 2004-11-10 2012-02-07 Incyte Corporation Lactam compounds and their use as pharmaceuticals
KR101368228B1 (ko) * 2004-11-10 2014-02-27 인사이트 코포레이션 락탐 화합물 및 약제로서의 이의 용도
US20060142319A1 (en) * 2004-12-14 2006-06-29 Bang-Chi Chen Pyridyl-substituted spiro-hydantoin crystalline forms and process
US7186727B2 (en) * 2004-12-14 2007-03-06 Bristol-Myers Squibb Company Pyridyl-substituted spiro-hydantoin compounds and use thereof
EP1828192B1 (en) * 2004-12-21 2014-12-03 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US20080033027A1 (en) * 2005-03-21 2008-02-07 Vicus Therapeutics Spe 1, Llc Drug combination pharmaceutical compositions and methods for using them
EP1990049A3 (en) * 2005-03-21 2008-11-26 Vicus Therapeutics SPE 1, LLC Combination therapy of beta-blockers and non-steroidal anti-inflammatory drugs (NSAID)
US20090117197A1 (en) * 2005-03-21 2009-05-07 Vicus Therapeutics Llc Compositions and methods for ameliorating cachexia
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
JP2009507791A (ja) * 2005-08-29 2009-02-26 メルク エンド カムパニー インコーポレーテッド ナイアシン受容体アゴニスト、このような化合物を含有する組成物、および治療方法
PL1931350T5 (pl) * 2005-09-14 2021-11-15 Takeda Pharmaceutical Company Limited Podanie inhibitorów dipeptydylo-peptydazy
EP2073810B1 (en) * 2006-09-13 2011-08-31 Takeda Pharmaceutical Company Limited Use of 2-6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-ylmethyl-4-fluoro-benzonitrile for treating diabetes, cancer, autoimmune disorders and hiv infection
AU2006290205B2 (en) * 2005-09-14 2012-12-13 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors for treating diabetes
TW200745079A (en) * 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor
TW200745080A (en) * 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of tartrate salt of 2-[2-(3-(R)-amino-piperidin-1-yl)-5-fluoro-6-oxo-6H-pyrimidin-1-ylmethyl]-benzonitrile and methods of use therefor
CA2622642C (en) * 2005-09-16 2013-12-31 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
CN102304075A (zh) * 2005-10-11 2012-01-04 因特蒙公司 病毒复制抑制剂
US8926990B2 (en) 2009-10-13 2015-01-06 Rutgers, The State University Of New Jersey Treatment and diagnosis of inflammatory disorders and HIV
CN101032483B (zh) * 2006-03-09 2011-05-04 陈德桂 调节雄激素受体活性的乙内酰脲衍生物及其应用
ES2689292T3 (es) 2006-03-27 2018-11-13 The Regents Of The University Of California Modulador del receptor de andrógenos para el tratamiento del cáncer de próstata y enfermedades asociadas con el receptor de andrógenos
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US20100029941A1 (en) * 2006-03-28 2010-02-04 Takeda Pharmaceutical Company Limited Preparation of (r)-3-aminopiperidine dihydrochloride
NZ572374A (en) 2006-03-29 2011-12-22 Univ California Diarylthiohydantoin compounds
US7740064B2 (en) 2006-05-24 2010-06-22 Baker Hughes Incorporated System, method, and apparatus for downhole submersible pump having fiber optic communications
RU2009110254A (ru) 2006-08-24 2010-09-27 Новартис АГ (CH) Производные 2-(пиразин-2-ил)тиазола и 2-(1н-пиразол-3-ил)тиразола и связанные с ним соединения в качестве ингибиторов стеароил-соа десатуразы для лечения метаболических, сердечно-сосудистых и других нарушений
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
CN101516877B (zh) 2006-09-22 2013-09-11 诺瓦提斯公司 杂环有机化合物
TW200838536A (en) * 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
EP2121671A1 (en) 2006-12-20 2009-11-25 Novartis AG 2-substituted 5-membered heterocycles as scd inhibitors
EP2128163A1 (en) 2007-01-25 2009-12-02 Takeda Pharmaceutical Company Limited Spiro-ring compound
US8575167B2 (en) 2007-02-06 2013-11-05 Takeda Pharmaceutical Company Limited Spiro compounds having stearoyl-CoA desaturase action
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
US8258313B2 (en) * 2007-07-19 2012-09-04 Tokuyama Corporation Compound having hydantoin ring and method of producing the same
MX2010004281A (es) 2007-10-19 2010-09-10 Sarcode Corp Composiciones y metodos para el tratamiento de la retinopatia diabetica.
EP2220050A2 (en) 2007-10-26 2010-08-25 The Regents Of The University Of California Diarylhydantoin compounds as androgen receptor modulators
US20090170770A1 (en) * 2007-11-06 2009-07-02 Ali Hafezi-Moghadam Methods and compositions for treating conditions associated with angiogenesis using a vascular adhesion protein-1 (vap 1) inhibitor
EP2445914B1 (en) 2009-06-02 2015-07-22 Boehringer Ingelheim International GmbH DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-a]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES
CA2773038A1 (en) 2009-09-04 2011-03-10 P. Jeffrey Conn Mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
SG10201907588XA (en) 2010-02-16 2019-09-27 Aragon Pharmaceuticals Inc Androgen Receptor Modulators And Uses Thereof
US9724351B2 (en) 2012-08-23 2017-08-08 Alios Biopharma, Inc. Compounds for the treatment of paramoxyvirus viral infections
CN115737643A (zh) 2012-09-26 2023-03-07 阿拉贡药品公司 用于治疗非转移性去势抵抗性前列腺癌的抗雄激素
DK2945628T3 (da) 2013-01-15 2020-05-04 Aragon Pharmaceuticals Inc Androgen receptormodulator i kombination med abirateronacetat og prednison til behandling af prostatacancer
PH12021550330A1 (en) * 2013-08-21 2022-09-28 Janssen Biopharma Inc Antiviral compounds
CR20160496A (es) * 2014-04-04 2017-01-02 X-Rx Inc Inhibidores espirocíclicos sustituidos de la autotaxina
WO2016028971A1 (en) 2014-08-21 2016-02-25 Bristol-Myers Squibb Company Tied-back benzamide derivatives as potent rock inhibitors
MA41614A (fr) 2015-02-25 2018-01-02 Alios Biopharma Inc Composés antiviraux
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
US10610520B2 (en) 2016-03-31 2020-04-07 Takeda Pharmaceutical Company Limited Heterocyclic compound
MX2020003845A (es) 2017-10-16 2020-11-06 Aragon Pharmaceuticals Inc Antiandrógenos para el tratamiento de cáncer de próstata no metastásico resistente a la castración.
JP2024502909A (ja) * 2020-12-24 2024-01-23 アルマルソン、オーン キサントフィル誘導体
CN115536494B (zh) * 2022-10-31 2023-12-01 苏州诚和医药化学有限公司 1-(4-溴苯基)-1,4-丁二醇的合成方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1331757C (en) * 1988-02-29 1994-08-30 Janssen Pharmaceutica Naamloze Vennootschap 5-lipoxygenase inhibiting 4-(4-phenyl-1-piperazinyl)phenols
US5346913A (en) * 1992-05-26 1994-09-13 Rohm And Haas Company N-iodopropargyl hydantoin compounds, compositions, preparation, and use as antimicrobial agents
FR2694290B1 (fr) * 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines éventuellement substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
TW521073B (en) * 1994-01-05 2003-02-21 Hoechst Marion Roussel Inc New optionally substituted phenylimidazolidines, their preparation process, their use as anti-androgenic agent and the pharmaceutical compositions containing them
FR2741342B1 (fr) * 1995-11-22 1998-02-06 Roussel Uclaf Nouvelles phenylimidazolidines fluorees ou hydroxylees, procede, intermediaires de preparation, application comme medicaments, nouvelle utilisation et compositions pharmaceutiques
JP2004535411A (ja) 2001-05-25 2004-11-25 ブリストルーマイヤーズ スクイブ カンパニー マトリックスメタロプロテナーゼ及び／またはＴＮＦ−α転換酵素（ＴＡＣＥ）の阻害剤としてのヒダントイン及び関連複素環化合物

Also Published As

Publication number Publication date
DE60234264D1 (de) 2009-12-17
NZ531870A (en) 2005-08-26
JP2005510476A (ja) 2005-04-21
HRP20040311A2 (en) 2005-02-28
PE20030845A1 (es) 2003-10-23
IL160990A0 (en) 2004-08-31
US20040009998A1 (en) 2004-01-15
IS7197A (is) 2004-03-24
GEP20063767B (en) 2006-03-10
CA2462112A1 (en) 2003-04-10
EP1432700B1 (en) 2009-11-04
BR0213025A (pt) 2004-10-05
ATE447565T1 (de) 2009-11-15
US7078420B2 (en) 2006-07-18
US20050004153A1 (en) 2005-01-06
NO20041339D0 (no) 2004-03-31
HK1063467A1 (en) 2004-12-31
HUP0402338A3 (en) 2008-10-28
EP1432700A1 (en) 2004-06-30
CN1596253A (zh) 2005-03-16
PL369337A1 (en) 2005-04-18
JP4394442B2 (ja) 2010-01-06
AR036663A1 (es) 2004-09-22
MXPA04002993A (es) 2004-07-15
US20040248920A1 (en) 2004-12-09
US20040259897A1 (en) 2004-12-23
WO2003029245A1 (en) 2003-04-10
EP1432700A4 (en) 2004-12-22
HUP0402338A2 (hu) 2005-02-28
US6977267B2 (en) 2005-12-20
ES2339107T3 (es) 2010-05-17
KR20040041649A (ko) 2004-05-17
RS26604A (sr) 2006-12-15

Similar Documents

Publication Publication Date Title
NO20041339D0 (no) Spiro-hydantoin-forbindelser anvendelige som anti-inflammatoriske midler
NO20014412D0 (no) Forbindelser nyttige som anti-inflammatoriske midler
ATE309997T1 (de) Entzündungshemmende benzimidazolverbindungen
NO20033969D0 (no) Triazolpyridiner som anti-inflammatoriske midler
IS6971A (is) Ný efnasambönd
NO20042955L (no) Substituerte fenylaftalener som estrogene midler
DK1414803T3 (da) Pyrazolylcarboxanilider som fungicider
NO20035775L (no) 3-fluor-pyrrolidiner som anti-diabetesmidler
DK1429607T3 (da) Delta-1-pyrroliner som pesticider
DK1261588T3 (da) Imidazolforbindelser som alfa2-adrenoceptorantagonister
SE0104342D0 (sv) New compounds
SE0101659D0 (sv) New compounds
SE0100272D0 (sv) New compounds
SE0104366D0 (sv) New compounds
SE0103437D0 (sv) New compounds
SE0103461D0 (sv) New compounds
SE0102056D0 (sv) New Compounds
SE0102386D0 (sv) New compounds
SE0100629D0 (sv) New compounds
SE0101958D0 (sv) New compounds
SE0101660D0 (sv) New compounds
SE0104262D0 (sv) Chemical compound
SE0101239D0 (sv) Pharmaceutically useful compounds
SE0100966D0 (sv) Novel compounds
SE0102094D0 (sv) Novel compounds

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application